Resolvin D1 reprograms energy metabolism to promote microglia to phagocytize neutrophils after ischemic stroke

Cell Rep. 2023 Jun 27;42(6):112617. doi: 10.1016/j.celrep.2023.112617. Epub 2023 Jun 6.

Abstract

Neutrophil aggregation and clearance are important factors affecting neuroinflammatory injury during acute ischemic stroke. Emerging evidence suggests that energy metabolism is essential for microglial functions, especially microglial phagocytosis, which determines the degree of brain injury. Here, we demonstrate that Resolvin D1 (RvD1), a lipid mediator derived from docosahexaenic acid (DHA), promotes the phagocytosis of neutrophils by microglia, thereby reducing neutrophil accumulation in the brain and alleviating neuroinflammation in the ischemic brain. Further studies reveal that RvD1 reprograms energy metabolism from glycolysis to oxidative phosphorylation (OXPHOS), providing sufficient energy for microglial phagocytosis. Moreover, RvD1 enhances microglial glutamine uptake and stimulates glutaminolysis to support OXPHOS to boost ATP production depending on adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) activation. Overall, our results reveal that RvD1 reprograms energy metabolism to promote the microglial phagocytosis of neutrophils after ischemic stroke. These findings may guide perspectives for stroke therapy from modulating microglial immunometabolism.

Keywords: CP: Immunology; Resolvin D1; immunometabolism; ischemic stroke; microglia; neutrophil; phagocytosis; reprogram energy metabolism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Energy Metabolism
  • Humans
  • Ischemic Stroke* / metabolism
  • Microglia / metabolism
  • Neutrophils*

Substances

  • resolvin D1